- Science / Human: Cannabis improves survival of patients with an aggressive brain tumor in a controlled study
A cannabis extract with THC and CBD improved the survival of patients with a glioblastoma, a particularly aggressive brain tumor, when it was administered with standard therapy. This is the result of a placebo-controlled study with 21 patients, which the producer of cannabis extract Sativex GW Pharmaceuticals from Great Britain published. 12 patients received Sativex together with Telozolomid, and 9 patients received Telozolomid and a placebo.
The study showed that 83% of patients with a documented glioblastoma relapse treated with THC and CBD were still alive after one year, compared to 53% in patients in the placebo group (p = 0.042). The average survival in the cannabis group was more than 550 days, compared to 369 days in the placebo group. In the press release it is called: “GW has investigated substantial pre-clinical and logical studies with different cannabinoids in different cancers, including the brain, lungs, breasts, pancreas, melanoma, uterus, stomach, kidneys, prostate and urinary bladder. These studies have led to around 15 publications and show the multi-modal effect of cannabinoids on a number of key signal pathways associated with the growth and continuation of tumors. ”
Press release by GW Pharmaceuticals or 7 February 2017
- Science / cells: Stem cells treated with CBD can be useful in the treatment of Alzheimer’s disease
Mesenchymal stem cells have often emerged as a promising tool for the treatment of neurodegenerative diseases, including Alzheimer’s disease. A study shows that the pretreatment of these cells with CBD (cannabidiol) “shows a molecular profile that could be useful in the treatment” of Morbus Alzheimer’s.
IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy.
Libro R, et al. Int J Mol Sci. 2016 December 23rd. 18 (1).
- Science / human: Cannabidiol can be useful in schizophrenia according to clinical research
The cannabinoid cannabidiol (CBD) plant has been shown in a clinical trial as a possible new treatment for psychosis, scientists at King’s College in London, UK wrote. In the study, 88 patients received 1000 mg CBD or placebo in addition to their existing antipsychotic medication for six weeks. Patients treated with CBD had lower levels of psychotic symptoms than those who received placebo.
The study found that patients treated with CBD were more likely to be assessed as “improved” by their psychiatrist and that there were signs of improved cognitive performance. Authors conclude in their article that these findings suggest that CBD has beneficial effects in patients with schizophrenia. Because CBD effects do not appear to be dependent on dopamine receptor antagonism, this substance may constitute a new treatment class for this condition. ”
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an adjunctive therapy for schizophrenia: a multicenter randomized controlled study. Ben J. Psychiatry. December 15, 2017 [in print]
Reuters or December 15, 2017
WHO: No reports on abuse of CBD relatedness
During the thirty-ninth session of November 6-10, 2017, the WHO expert committee on drug addiction discussed the status of cannabidiol (CBD) with regard to controlled substances under the United Nations Conventions. The report says that “there are no application reports of abuse of involvement regarding the use of pure CBD. There are also no published statistics on non-medical use of pure CBD. ”
CBD.pdf ”> CANNABIDIOL (CBD): Pre-Review report
WHO: CBD should not be planned as an internationally regulated substance
At its November 2017 meeting, the WHO Expert Committee on Drug Addiction (ECDD) concluded that cannabidiol (CBD) does not appear to have any visible signs of abuse or harm. CBD is not an important material at the moment and current information does not justify a change in this position.
World Health Organization, December 2017